Ordering RecommendationRecommendations when to order or not order the test. May include related or preferred tests.
Recommended initial test in the evaluation of suspected hyperandrogenemia in women and children. Acceptable test for evaluating androgen deficiency in men.
MnemonicUnique test identifier.
MethodologyProcess(es) used to perform the test.
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry/Electrochemiluminescent Immunoassay The concentration of free testosterone is derived from a mathematical expression based on the constant for the binding of testosterone to sex hormone binding globulin.
PerformedDays of the week the test is performed.
ReportedExpected turnaround time for a result, beginning when ARUP has received the specimen.
New York DOH Approval StatusIndicates test has been approved by the New York State Department of Health.
This test is New York DOH approved.
Collect between 6-10 a.m.
Serum separator tube or green (sodium or lithium heparin).
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.8 mL)
This test is suggested for women and children due to an improved sensitivity of testosterone by LC-MS/MS.
After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 6 months
Reference IntervalNormal range/expected value(s) for a specific disease state. May also include abnormal ranges.
Interpretive DataBackground information for test. May include disease information, patient result explanation, recommendations, details of testing, associated diseases, explanation of possible patient results.
The concentration of free testosterone is derived from a mathematical expression based on the constant for the binding of testosterone to sex hormone binding globulin.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
NoteAdditional information related to the test.
This test is suggested for women and children due to an improved sensitivity of testosterone by LC-MS/MS. Please refer to individual components for stability of sample for this test.
CPT CodesThe American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
AliasesOther names that describe the test. Synonyms.
Testosterone, Free and Total (Includes Sex Hormone Binding Globulin), Females or Children